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Severity of pain (BPI-item-3) was statistically associated with
total annual health costs; €1255 (932), €1473 (1198) and
€1950 (1391) for mild, moderate and severe pain respectively,
p = 0.017. Walking (FIQ1g) and work/domestic (BPI5d) inter-
ference were positive predictors for per patient annual drug
costs, while pain problems and 12-month health state change
(EQ-5D items 4 and 6) were negative predictors (R2 = 0.283,
p < 0.001). CONCLUSION: In the primary care setting, annual
per patient total direct health cost of Fibromyalgia showed
weak but statistically signiﬁcant association with patient disease
interference and severity of pain. Less drug costs could be asso-
ciated with poorer outcomes in term of health state change and
level of pain.
OBESITY—Clinical Outcomes Studies
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OBJECTIVES: To describe the association between obesity and
costs and use of antipsychotic drugs (APDs) in patients seen by
seven Spanish primary care teams (PCTs), under usual medical
practice. METHODS: A retrospective, multicenter study was
made with patients receiving APD treatment during year 2005.
Obesity was considered according to W.H.O. as a body mass
index (BMI) > 30 kg/m2. Main measurements included APD
consumption, sociodemographics, comorbidity/episodes, Charl-
son index (severity), and costs (semi-ﬁxed and variable, visits,
diagnostic/therapeutic procedures, referrals and drugs). Descrip-
tive statistics, logistic regression model and analysis of covari-
ance (ANCOVA) with Bonferroni correction were applied.
RESULTS: A total of 42,437 patients (age: 50.9  17.8 years,
women: 59.9%) were included in the analysis. Obesity was
present in 27.3% [CI: 26.9–27.7%]), with a 1.3% receiving
APDs (typical: 48.8%, atypical: 51.2%; p = NS). Patients with
obesity showed higher annual average of episodes (7.0  4.0
vs. 5.5  3.6), visits (12.1  9.8 vs. 9.1  8.5) and severity
(0.5  0.7 vs. 0.3  0.6), p < 0.001. In the logistic regression
analysis, obesity was related to APD use (OR = 1.5; CI: 1.3–
1.8), hypertension (OR = 2.4; CI: 2.2 2.5), diabetes (OR = 1.4;
CI: 1.3–1.5) and dyslipidemia (OR = 1.3; CI: 1.2–1.4),
p < 0.001 in all cases. After adjusting, BMI was slightly higher
in subjects on APD; 27.8 kg/m2 vs. 27.4 kg/m2, p = 0.002.
Mean crude and adjusted (age, gender and comorbidities)
annual costs were signiﬁcantly higher in obese patients than
in non obese; €980.89  1,467.49 vs. €637.64  1,244.49,
p < 0.001, and €810.88 vs. €693.79, p < 0.001 respectively. All
components of per patient per year costs were higher in the
group of obese patients, p < 0.0001. CONCLUSION: Obesity
was associated with the use of APDs and the presence of hyper-
tension, diabetes and dyslipidemia. No differences were found
between using typical or atypical APDs. Obese patients pre-
sented more comorbidity, use of health resources and associated
costs.
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OBJECTIVES: Clinical trials have demonstrated that rimona-
bant leads to signiﬁcant improvements in cardiometabolic risk
factors, including weight, waist circumference, lipids, and fasting
glucose. This study translates these beneﬁts into expected out-
comes when rimonabant is administered to adults with dyslipi-
demia and a BMI>27 kg/m2 in addition to diet and exercise.
METHODS: A discrete event simulation was developed to
project outcomes in individuals at increased cardiometabolic
risk. Data from the Health Survey of England are used to create
simulated adults free of cardiovascular disease (CVD) and dia-
betes but who are overweight or obese and have either elevated
triglycerides or low HDL. Equations derived from the RIO trials
are used to calculate changes in individual cardiometabolic risk
factors as a function of time, treatment and baseline risk factors.
Treatments considered are diet and exercise alone or with the
addition of rimonabant 20mg. The simulation determines when
individuals develop CVD, diabetes, or microvascular disease
(MVD) using published equations from Framingham, UKPDS
and the San Antonio Heart Study. RESULTS: After one year,
simulated patients on rimonabant lose an average of 4.4 kg com-
pared to only 0.4 kg with diet and exercise alone. On average
HDL levels increase by 0.07 mmol/L more with rimonabant;
triglyceride levels fall by 0.27 mmol/L more. Over their lifetimes,
1000 rimonabant users experience 9 fewer CVD events, live 66
years longer, and avoid 334 years with diabetes. MVD events fall
by 30. Extending treatment to 10 years results in 11% fewer
CVD events and life expectancy gains of 234 years compared to
one year of treatment. CONCLUSION: These results suggest
that in overweight or obese patients with dyslipidemia, cardi-
ometabolic risk factor improvements associated with rimona-
bant, which extend beyond those expected with diet and exercise
alone, could translate to concrete health gains by preventing or
delaying diabetes, MVD and acute CVD.
OBESITY—Methods and Concepts
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OBJECTIVES: The WinBUGS software is a powerful tool to
analyze data in the framework of the bayesian theory and has
recently been shown useful in developing complex probabilistic
Markov models. Despite some clear advantages, this technique
has not been fully exploited in health economic evaluations. We
developed a cost-utility and budget impact analysis of the use of
orlistat in Italian obese patients through this innovative model-
ling approach. METHODS: A probabilistic Markov model has
been developed to simulate outcomes of the obese Italian popu-
lation after four years of orlistat treatment plus six years of
follow-up. The efﬁcacy of the treatment derives from the
XENDOS study. The model integrates a Framingham Heart
Study-based algorithm to estimate cardiovascular risk. The
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